How a Cure Cancer-backed researcher just made it into Nature

A researcher supported by Cure Cancer has reached a remarkable milestone, with his work on how diet shapes immune cell survival published in Nature, one of the most prestigious scientific journals in the world.

Dr Anthony Zhian Chen, a Senior Research Fellow and Group Leader at the University of Queensland's Frazer Institute, is a joint first author on the paper "Lipid metabolism drives dietary effects on T cell ferroptosis and immunity." The discovery reveals a surprising connection between what we eat and how effectively our immune system can respond to cancer.

A discovery hiding in plain sight

At the centre of this research is a process called ferroptosis, a specific type of cell death that happens when cells become overwhelmed by a particular kind of internal damage and can no longer survive.

T cells are the immune system's frontline defenders against cancer. They seek out and destroy cancer cells, but they are also surprisingly fragile. When too many T cells die prematurely, the immune system loses its ability to respond effectively, and cancer has then more room to grow.

What Dr Chen and his collaborators discovered is that T cells do not have a fixed lifespan. How long they survive depends, in part, on the balance of fats in our diet. Specifically, the ratio of two types of dietary fat, polyunsaturated fatty acids and monounsaturated fatty acids, plays a direct role in how well T cells hold up under pressure. The research also found this same pattern in human T cells, pointing to a mechanism that may be shared across people and that could one day be used to improve how cancer treatments work.

Why this matters for cancer

The implications reach beyond basic biology. This research points to the possibility of strategically manipulating diet-derived lipid levels to boost the quality of adaptive immunity, including in the context of cancer immunotherapy and vaccines.

For people undergoing T cell-based cancer treatments, including emerging CAR T cell therapies, understanding what keeps these immune cells active and alive could be the difference between a treatment that works and one that doesn't.

This is not a simple "eat this, cure cancer" story. It is something more foundational: evidence that the biological environment we create through nutrition shapes the tools our immune system has available when it needs them most.

Driven by something personal

For Dr Chen, this work is not only about scientific discovery. He has watched family members receive a cancer diagnosis, and that experience sits at the heart of why he does this work.

"I have witnessed my family members unfortunately diagnosed with cancers, and I hope that my research can eventually benefit the patients like them," he says.

"I believe that accumulated small steps in advancing our knowledge of the immune system can lead to significant advancements in therapies and, ultimately, better outcomes for patients."

A researcher with bigger questions still ahead

The Nature publication is not the endpoint of Dr Chen's work. With support from Cure Cancer's research grants program, he is now investigating a different piece of the same puzzle: how to keep the immune system's cancer-killing cells switched on for longer.

These cells, known as CD8+ T cells, are among the body's most powerful tools against cancer. The problem is that in the presence of cancer, they can gradually lose their ability to function, almost like a battery running flat. Dr Chen is studying a signalling molecule called interleukin-21, which may hold the key to preventing that from happening and, ultimately, to building more effective cancer treatments.

It is a different question to the ferroptosis research, but the thread connecting them is the same: what does it take for our immune cells to stay strong enough to do their job?

Dr Chen credits the grant as a turning point. "The generous funding from the Cure Cancer grant is fundamental for my career journey. It will provide vital support for the proposed research."

He is also candid about the pressures facing emerging researchers: "Maintaining the original passion for research and focusing on the next crucial experiment helps me to sustain resilience and enthusiasm during some challenging periods."

The value of early support

Dr Chen's research program has already produced publications as first or joint first author in top-tier journals including Nature Immunology, Science Immunology, and Nature Communications. The Nature paper brings that record to a new level, and reflects years of sustained effort to understand the biology that underpins cancer immunity.

For Cure Cancer supporters, this is exactly what early investment looks like in practice. Before a researcher has the track record to attract large-scale funding, someone has to believe the questions are worth asking.

That is what your support makes possible.

What if the next breakthrough just needs you?